Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of the glycemic efficacy of cabergoline on diabetic patients

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sherief Abd-Elsalam; Tanta University
• Treatments: Cabergoline; Gliclazide

Criteria

Inclusion Criteria:

• Diabetic patients.

Exclusion Criteria:

• Other drugs administration